GHRH Analog • Growth Hormone Support
Stimulate Natural Growth Hormone Production
CJC-1295 (no DAC) is a growth hormone-releasing hormone (GHRH) analog that stimulates your pituitary gland to naturally produce more growth hormone. Unlike synthetic HGH, it works with your body's own rhythms to support recovery, body composition, and vitality. Join our waitlist to be notified when available.
GHRH
Analog (Mod GRF 1-29)
Pulsatile
GH Release Pattern
~30
Minute Half-Life
1-3x
Daily Dosing
Growth Hormone Support
A modified GHRH analog that stimulates natural growth hormone release while preserving the body's pulsatile secretion pattern—the way GH is meant to be released.
5mg per vial
Ideal For
Adults seeking to optimize growth hormone levels naturally for improved recovery, body composition, sleep quality, and overall vitality.
The Science
CJC-1295 (no DAC), also known as Modified GRF (1-29) or Mod GRF, is a synthetic analog of growth hormone-releasing hormone (GHRH). It signals your pituitary gland to produce and release more growth hormone naturally, rather than introducing synthetic HGH from outside the body.
The "no DAC" version has a short half-life of approximately 30 minutes, which preserves the body's natural pulsatile pattern of GH release. This is important because growth hormone is normally released in pulses, not continuously—and maintaining this rhythm may reduce the risk of receptor desensitization.
In a 2006 study of the long-acting DAC version of CJC-1295, a single injection raised GH levels 2-10 fold and IGF-1 levels 1.5-3 fold; the shorter-acting no-DAC form produces brief pulses and has not been studied the same way. It's often combined with a growth hormone secretagogue like Ipamorelin for synergistic effects—the GHRH analog amplifies the signal while the secretagogue triggers the release.
Schedule Consultation
How It Works
CJC-1295 works by mimicking your body's natural growth hormone-releasing hormone, stimulating the pituitary to produce more GH on its own.
Binds to GHRH receptors on pituitary somatotroph cells, signaling them to synthesize and release growth hormone into circulation.
The short half-life (~30 min) allows GH to be released in natural pulses rather than sustained elevation, preserving physiologic rhythm.
Elevated GH stimulates the liver to produce IGF-1, which mediates many of growth hormone's anabolic and regenerative effects throughout the body.
Understanding Your Options
The "no DAC" version offers a more physiologic approach to growth hormone optimization compared to the long-acting DAC version.
*Individual responses vary. Consult with our physicians to determine the best approach for your goals.
Potential Benefits
Signals your pituitary to produce its own growth hormone rather than introducing synthetic HGH—working with your body's natural systems.
Higher GH and IGF-1 levels may support tissue repair, muscle recovery after exercise, and overall healing processes.
Growth hormone optimization may support increased lean muscle mass and reduced body fat when combined with proper nutrition and exercise.
GH is naturally released during deep sleep. Optimizing GH levels may support more restorative sleep cycles and overall sleep quality.
Often combined with Ipamorelin or other GH secretagogues for enhanced effects—the GHRH analog amplifies what the secretagogue triggers.
GH and IGF-1 decline with age. Restoring more youthful levels may support skin health, energy, cognitive function, and overall vitality.
Your Journey
Our medical team guides you through every step of growth hormone optimization—from initial evaluation to ongoing monitoring.
Meet with our physician to discuss your goals, review health history, and determine if peptide therapy is appropriate for you.
Baseline testing including IGF-1, metabolic panel, and other relevant markers to assess your current hormone status.
Your physician designs a personalized protocol—often combining CJC-1295 with Ipamorelin—tailored to your specific needs and goals.
Regular follow-ups to monitor progress, adjust dosing as needed, and review how you are responding.
Safety & Candidacy
CJC-1295 therapy requires proper medical evaluation and monitoring. Our physicians will assess whether you're a good candidate based on your health history and goals.
GHRH
Analog that stimulates your body's own growth hormone production
~30 min
Short half-life preserves natural pulsatile GH release pattern
At a glance
Your plan
The visit starts with what you actually want to change, such as recovery between sessions, sleep quality or body composition, and what you have already tried. Secretagogue peptides only make sense when the basics are in place, because a pituitary signal cannot make up for short sleep, under-eating protein or overtraining, so training, sleep and nutrition are part of the conversation, not an afterthought.
Baseline IGF-1 is the main steering number for any growth hormone-axis plan. A fasting glucose or HbA1c, a metabolic panel and, depending on age and history, cancer-screening status are reviewed too, because raising growth hormone signaling is not appropriate for everyone.
The provider decides whether CJC-1295 no DAC on its own, the pre-paired CJC-1295 and ipamorelin vial, or a different approach suits you. The choice depends on your IGF-1, how sensitive you are to side effects, and whether you want the extra ghrelin-receptor signal that ipamorelin adds. The written plan explains timing, storage and what to report. The dose is set at the visit, not here.
Two to four weeks in, the clinic asks about flushing after injections, headaches, water retention, tingling in the hands and sleep. These are the effects most likely to need an adjustment. The check-in is also where timing gets fine-tuned; moving an injection relative to a meal or a workout sometimes matters as much as the dose.
IGF-1 and glucose are rechecked during or at the end of the block. If IGF-1 is already toward the top of the age-appropriate range, the provider will not push it higher, even if you feel you want more effect. If IGF-1 barely moved and you noticed nothing, that is useful information too, and the honest next step may be to stop rather than escalate.
Timeline
Mostly routine-building. Some people notice warmth or flushing for a few minutes after an injection; that usually fades with time. Injection technique, site rotation and refrigeration are covered at the first visit so the routine is settled before anyone judges results.
Reports of deeper sleep or easier recovery tend to appear here, though they are subjective and not universal. Lab changes in IGF-1 are the more reliable signal. Keep a simple log of sleep and training so the review is based on more than memory.
Any body-composition change is gradual and depends far more on training and diet than on the peptide. Progress photos and a consistent scale or body-composition scan help separate real change from wishful thinking.
A planned pause and a lab review. A further block is decided on IGF-1, side effects and whether your goals moved, not on habit. Some people use the pause to see whether the sleep or recovery changes they noticed persist without the peptide, which helps decide whether another block is worth it.
Compare
| Option | How it acts | Practical difference | Status |
|---|---|---|---|
| CJC-1295 no DAC (this page) | Short GHRH signal, minutes to hours | Timed injections; easy to pause or adjust | Compounded; not FDA-approved |
| CJC-1295 + ipamorelin vial | GHRH signal plus a ghrelin-receptor signal | One injection covers both pathways | Compounded; not FDA-approved |
| Sermorelin | GHRH (1-29), the older reference peptide | Longest clinical history of the GHRH fragments | Compounded; not FDA-approved as currently supplied |
| Lifestyle-only approach | Deep sleep, resistance training, adequate protein | Supports the body's own growth hormone pulses without injections | No prescription required |
| Tesamorelin | Stabilized full-length GHRH analog | FDA-approved only for a specific HIV-related fat indication | Brand product approved; compounded use is off-label |
Is it right for you?
Monitoring
IGF-1 is the anchor. Because growth hormone itself pulses and is hard to measure in a single blood draw, IGF-1 gives a steadier read of what the plan is doing. The goal is a value that sits sensibly for your age, not the highest number possible; pushing past that range adds risk without a known benefit.
Glucose control is the second watch point. Growth hormone opposes insulin, so a fasting glucose or HbA1c is repeated during the block, more often if you have prediabetes. Water retention, joint aches, numbness or tingling in the hands, and persistent headaches are reasons to call the clinic. Flushing right after an injection is common and usually brief, but a racing heart, fainting or chest symptoms are not expected and need prompt medical attention.
FDA's safety summary for CJC-1295 mentions reports of increased heart rate and a systemic vasodilatory reaction, with limited clinical data overall, so the clinic asks about palpitations and lightheadedness at every check-in.
Finally, the clinic records the compounding pharmacy, lot and beyond-use date for every vial. Pre-mixed peptide vials need refrigeration and a clean technique each time; a vial that looks cloudy, has particles or was left warm should not be used, and you should ask for a replacement rather than guess.
Regulatory status
Regulatory status: CJC-1295 is not an FDA-approved drug, and BHRC's vials are compounded preparations that FDA has not evaluated for safety, effectiveness or quality. FDA previously placed CJC-1295 in Category 2 of its 503A bulk substances interim policy, citing immunogenicity and impurity concerns and reports of serious adverse events including increased heart rate and systemic vasodilatory reaction. FDA's list, last updated April 22, 2026, shows CJC-1295 among substances whose nominations were withdrawn by the nominators. BHRC prescribes it only after a consultation and baseline labs with a licensed provider. It is not intended to diagnose, treat, cure or prevent any disease. Prepared by the BHRC team from FDA and PubMed sources.
Before you book
Cost depends on whether you use the single peptide or the paired vial, how long the block runs, how many vials that needs and which labs are repeated. BHRC does not post prices on this page; you get a quote after the consult, and membership pricing may apply if you are enrolled in a BHRC membership.
The single-peptide vial currently shows a waitlist on this page. If your provider thinks a growth hormone-axis plan is appropriate, the paired CJC-1295 and ipamorelin vial or sermorelin may be discussed as alternatives while you wait.
BHRC lists the no-DAC form. The DAC version carries a drug affinity complex that lets it circulate for days; in a 2006 study of healthy adults, a single injection of the DAC form raised growth hormone and IGF-1 for a week or more. That long tail is the trade-off. A short-acting form can be paused within hours if a side effect appears, which suits a supervised plan. It also means the no-DAC form needs more frequent injections, so the decision is really between convenience and control. For a first growth hormone-axis plan, BHRC providers generally favor control.
Those numbers are from the 2006 study of CJC-1295 with DAC, the long-acting version, not from the no-DAC fragment. Older studies of GHRH (1-29) in healthy older men showed it could raise GH and IGF-1 toward younger-adult levels when given more than once a day, and that a single nightly dose was less effective. Individual results vary, and none of these studies tested the compounded product.
Timing is usually built around sleep or training because that is when natural growth hormone pulses occur. Your provider sets the schedule. For general background, see our CJC-1295 Dosage Guide, which is educational only.
The no-DAC fragment is cleared quickly, on the order of minutes, because the native GHRH sequence is broken down rapidly in the bloodstream, which is why it produces a short pulse rather than a sustained rise. That is the main practical difference from the DAC form and from growth hormone itself.
GHRH-type peptides and ghrelin-receptor peptides act on the pituitary through different receptors, and research in men has shown that combining the two signals produces more growth hormone release than either alone. BHRC offers a pre-paired vial for that reason; see the CJC-1295 and ipamorelin page.
No. Prescription growth hormone replaces the hormone directly. CJC-1295 no DAC depends on your pituitary responding, and the body's normal feedback still applies. That is also why results tend to be more modest. A secretagogue cannot push the system much beyond what your pituitary is able to produce, which acts as a built-in brake. People with genuine adult growth hormone deficiency need an endocrinology workup and are a different conversation entirely.
Brief flushing or warmth after injection, headache, injection-site redness and, with higher IGF-1, water retention or joint aches. Report palpitations or lightheadedness promptly. Most mild effects settle within the first couple of weeks or with a timing change; persistent ones are a reason to lower the dose or stop, which your provider decides.
BHRC strongly advises against it. Research-labeled vials are not intended for human use, may be mislabeled as DAC or no DAC, and come with no lab monitoring. A supervised plan exists precisely to catch the problems that unsupervised use misses.
Selected research
The literature below is peer-reviewed background on CJC-1295 (No DAC) and the mechanisms discussed on this page, so you can read the primary sources yourself. It is not evidence of any particular outcome at BHRC, and some of it is preclinical work in animals or cells. Your provider will discuss what the evidence does and does not support for your situation.
Related peptide therapies
Peptide therapy
Growth Hormone Secretagogue • Healthy Aging Support
Peptide therapy
Triple GH Optimization Blend
Questions
CJC-1295 without DAC (also called Mod GRF 1-29) has a short half-life of about 30 minutes, allowing for pulsatile GH release that mimics the body's natural pattern. CJC-1295 with DAC has a half-life of 6-8 days, causing sustained GH elevation. Most practitioners prefer the "no DAC" version because it's more physiologic and allows easier dose adjustment.
CJC-1295 stimulates your pituitary gland to produce its own growth hormone, while synthetic HGH (somatropin) introduces external growth hormone directly. The GHRH analog approach is considered more physiologic because it works through your body's natural feedback systems and preserves pulsatile release patterns.
CJC-1295 (a GHRH analog) and Ipamorelin (a growth hormone secretagogue) work through different mechanisms that complement each other. The GHRH analog amplifies the GH-releasing signal, while the secretagogue triggers the actual release. Together, they can produce greater GH elevation than either alone—this is called synergy.
Due to its short half-life, CJC-1295 no DAC is typically administered 1-3 times daily via subcutaneous injection. Common protocols include dosing before bed (to enhance natural nighttime GH release) or pre-workout. Your physician will design a protocol specific to your goals.
Results vary by individual, but potential benefits include improved recovery from exercise, better sleep quality, positive changes in body composition (more lean mass, less fat), improved skin quality, and enhanced overall vitality. Studies of GHRH (1-29) in older men showed increases in GH and IGF-1 when given more than once daily. Results typically develop over weeks to months of consistent use.
Common side effects may include flushing, headache, dizziness, nausea, and injection site reactions. These are typically mild and transient. Because GH can affect blood sugar and other metabolic parameters, proper medical supervision and monitoring are essential.
CJC-1295 is not appropriate for individuals with active cancer or history of certain cancers (GH can promote cell growth), pregnant or nursing women, or those with certain pituitary conditions. A thorough medical evaluation is required before starting therapy. Our physicians will review your complete health history to determine if you're a candidate.
Get Started
Schedule a consultation with our medical team to learn if CJC-1295 peptide therapy is right for your health and wellness goals.
"*" indicates required fields
Or call us directly: +1 213-325-3373
*CJC-1295 is a research peptide used in clinical settings for growth hormone optimization. The 2-10x GH and 1.5-3x IGF-1 figures sometimes quoted for CJC-1295 come from a published study of the long-acting DAC version, not the no-DAC form. Individual results vary. CJC-1295 therapy requires physician evaluation, baseline laboratory testing, and ongoing monitoring. It is not appropriate for individuals with active cancer, certain pituitary conditions, or other contraindications. This therapy should only be undertaken under proper medical supervision. Consult with our medical team to determine if you are a candidate.
